FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Debate over follow-ons focus on market exclusivity

The Boston Globe weighs in with a lengthy look at the tussle over biogenerics--a.k.a. follow-ons and biosimilars. The smart money is betting that at some point in the not-too-distant future Congress will get around to giving the FDA authority to approve biogenerics on a case-by-case basis. But don't expect the biotech lobbyists to back off of this issue anytime soon. As a concession, BIO is seeking 14-year market exclusivity for biotech drugs to compensate developers for the time it takes to gain approvals for these complex therapies. And they may come close: Lawmakers including Massachusetts' Ted Kennedy are backing a 12-year period of exclusivity.

- read the article in the Boston Globe

Related Articles:
Budget has mandate for biogeneric approvals. Report
Waiting game continues for biogenerics. Report
Dr. Reddy's make risky biogenerics move. Report
Lawmakers propose pathway for approving biosimilars. Report

More stories about FDA   biotech drugs   Regulation   Congress   Dr. Reddy   Biogenerics  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 64 + 16?
To combat spam, please solve the math question above.